Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial

Summary

To evaluate the effect of celecoxib use for 3 month after drug-eluting stent implantation * on restenosis * on clinical outcome such as target lesion revascularization, thrombotic event, myocardial infarction, death * on inflammatory biomarkers

Timeline

Start

2006-11

Primary completion

—

Completion

2009-10

Publications

• Background Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, Walsh K. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation. 2004 Jul 20;110(3):301-8. doi: 10.1161/01.CIR.0000135467.43430.16. Epub 2004 Jul 6.
• Background Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff AM, Penn MS. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol. 2005 Jan;45(1):61-7. doi: 10.1097/00005344-200501000-00011.

Drugs

Indications